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ABSTRACT
Introduction Neglected tropical diseases (NTDs) causing 
lower limb lymphoedema such as podoconiosis, lymphatic 
filariasis (LF) and leprosy are common in Ethiopia. Routine 
health services for morbidity management and disability 
prevention (MMDP) of lymphoedema caused by these 
conditions are still lacking, even though it imposes a huge 
burden on affected individuals and their communities in 
terms of physical and mental health, and psychosocial and 
economic outcomes. This calls for an integrated, holistic 
approach to MMDP across these three diseases.
Methods and analysis The ‘Excellence in Disability 
Prevention Integrated across NTDs’ (EnDPoINT) 
implementation research study aims to assess the 
integration and scale- up of a holistic package of care—
including physical health, mental health and psychosocial 
care—into routine health services for people with 
lymphoedema caused by podoconiosis, LF and leprosy 
in selected districts in Awi zone in the North–West of 
Ethiopia. The study is being carried out over three phases 
using a wide range of mixed methodologies. Phase 1 
involves the development of a comprehensive holistic care 
package and strategies for its integration into the routine 
health services across the three diseases, and to examine 
the factors that influence integration and the roles of 
key health system actors. Phase 2 involves a pilot study 
conducted in one subdistrict in Awi zone, to establish the 
care package’s adoption, feasibility, acceptability, fidelity, 
potential effectiveness, its readiness for scale- up, costs 
of the interventions and the suitability of the training and 
training materials. Phase 3 involves scale- up of the care 
package in three whole districts, as well as its evaluation 
in regard to coverage, implementation, clinical (physical 
health, mental health and psychosocial) and economic 
outcomes.
Ethics and dissemination Ethics approval for the study 
has been obtained in the UK and Ethiopia. The results will 
be disseminated through publications in scientific journals, 
conference presentations, policy briefs and workshops.
Strengths and limitations of this study
 ► The Excellence in Disability Prevention Integrated 
across NTDs (EnDPoINT) implementation research 
study takes a holistic approach in that it explores 
the full scope of processes and outcomes involved 
in the integration of physical health, mental health 
and psychosocial care for people with lower limb 
lymphoedema caused by podoconiosis, lymphatic 
filariasis and leprosy; integration of care relates to: 
(1) integration of care across the three diseases; (2) 
integration of care for these diseases into routine 
health services and (3) integration of mental health 
and psychosocial (including stigma reduction) inter-
ventions into holistic packages of care.
 ► EnDPoINT is guided by relevant conceptual per-
spectives on implementation research as well as 
employing a ‘Theory of Change’ approach towards 
devising, managing and evaluating the integration 
study.
 ► The study uses a wide range of mixed- method ap-
proaches across three phases to develop, scale- up 
and evaluate the holistic care package.
 ► Limitations of the study are: selection of study 
districts partly based on accessibility; time and re-
source constraints that do not allow the pilot study 
to have a control group or full- length follow- up 
before the scale- up; possible contamination of the 
study results by previous or ongoing work of other 
organisations in the study zone.
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INTRODUCTION
Neglected tropical diseases (NTDs) that result in lower 
limb lymphoedema, that is, swelling of the lower leg, 
include podoconiosis, lymphatic filariasis (LF) and 
leprosy. These conditions are common in Ethiopia, with 
an estimated 1.53 million cases of podoconiosis in the 
country,1 and around 300 000 people affected by leprosy.2 
The exact prevalence for LF lymphoedema in Ethiopia 
is less well known, since recent mapping studies have 
resulted in differing estimates3 4; however, integrated 
morbidity mapping in 2018 in 20 podoconiosis–LF coen-
demic districts identified a prevalence of 84.9 per 10 000 
population (26 123 cases in total), of whom 95.3% had 
leg lymphoedema only, 2.9% had hydrocele (swelling 
of the genitals in men), 1.5% had both leg lymphoe-
dema and hydrocele and 0.3% cases had breast lymph-
oedema.5 Nationwide mapping in 2013 demonstrated 
that podoconiosis accounts for approximately 64.8%, LF 
for 13.2% and leprosy for 12.8% of the total burden of 
lymphoedema in Ethiopia.6 With global burden estimates 
of 15 million, 4 million and 2–3 million for LF lymph-
oedema, podoconiosis and people affected by leprosy, 
respectively,7–9 improving morbidity management and 
disability prevention (MMDP) and enhancing our under-
standing of processes and outcomes of these efforts, in 
particular how to integrate MMDP into existing routine 
primary community- based healthcare services, are likely 
to be of global significance and address resource and 
sustainability questions.10
Lymphoedema imposes huge burdens on affected 
individuals and their communities in terms of disability 
such as reduced mobility and pain,11 mental distress,12 
depression and anxiety,13 14 stigma, discrimination and 
social exclusion,11 15–18 which can limit health- seeking 
behaviours and access to social services including educa-
tion, thereby leading to loss of economic productivity 
at household, community and national level.19–22 For 
podoconiosis in Ethiopia alone, affected people lose on 
average 45% of their economically productive time due 
to morbidity associated with the disease,20 and the esti-
mated cost to Ethiopia’s economy is US$213 million per 
year.23 These conditions therefore compromise the live-
lihoods and well- being of populations that are already 
disadvantaged and hard- to- reach, for example, because 
they live remotely.24 Burden of disease measures are even 
higher when taking into account the psychological and 
emotional consequences of NTDs, with estimates that the 
burden of these psychosocial outcomes may be double 
that of the physical health consequences.25
Along with the mental distress and disorder that 
commonly accompanies these NTDs, stigma is another 
key issue that significantly increases the disease burden 
for these diseases,25 and which acts as major barrier to 
accessing MMDP services.26 27 It is now widely recognised 
that joint approaches to reduce stigmatisation across 
NTDs may be feasible given the similarities in causes, 
manifestations and interventions,15 but there remains 
a knowledge gap in regards to relevant, evidence- based 
stigma reduction interventions for use within integrated 
MMDP programmes. Prior research suggests that stigma 
for lower limb lymphoedema has three main causes: (1) 
misinformation among the community, affected persons 
and their families about the diseases’ causes, treatment 
and prevention,16 28 which could be addressed through 
educational interventions providing standardised health 
information, to increase disease- related health literacy; 
(2) the common poverty and reduced quality of life due 
to affected individuals’ lost economic productivity,29 
which could be addressed through community- based 
socioeconomic rehabilitation/strengthening of affected 
individuals and their families and (3) the economic 
burden related to the costs of care, including transport to 
health facilities,16 30 which could be lessened by providing 
integrated services in nearby health facilities at low or 
no cost. Since multicomponent interventions are more 
effective than single- component interventions for stigma 
reduction, it is important for programmes to address all 
three causes of stigma (which the project described here 
attempts to do).
The WHO has published targets for elimination of 
many NTDs, including LF and leprosy31 32; however, 
this has not included podoconiosis (though podo-
coniosis has been included under LF for MMDP). 
While foot care for leprosy patients has been inte-
grated into routine health services in Ethiopia since 
2001,33 foot care interventions for podoconiosis and 
LF aiming to prevent disability are currently mainly 
provided through donor- supported projects in a 
disease- specific and disparate manner. Knowledge of 
these neglected diseases within healthcare systems is 
therefore often inadequate, diagnosis and treatment 
options are limited, and the cost of accessing health-
care to ease symptoms can be prohibitively expensive. 
On the other hand, the Ethiopian Federal Ministry 
of Health (FMOH) has developed integrated guide-
lines for LF and podoconiosis MMDP but these did 
not include leprosy (nor did they include mental 
health or psychosocial components). Yet, there is a 
clear rationale for the integration of care across these 
three conditions because of the shared clinical symp-
tomatology of lower leg lymphoedema. In addition, as 
the mental distress and illness that commonly accom-
panies lymphoedema12 13 34 often go untreated,35 
care can be enhanced further for affected people by 
adding mental health and psychosocial components 
to physical health services. Integration of care for 
lymphoedema can therefore include three aspects: 
Strengths and limitations of this study 
 ► The study team comprises an array of multidisciplinary academ-
ics and professionals in Ethiopia as well as internationally, includ-
ing medics, epidemiologists, psychiatrists, policy experts, social 
scientists, participatory intervention methodologists and affected 
persons.
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(1) integration of care across the three diseases; (2) 
integration of care for these diseases into routine 
health services and (3) integration of mental health 
and psychosocial (including stigma reduction) inter-
ventions into holistic packages of care. Integrated 
care models for NTDs have also been used in other 
countries.36 37
The Ethiopian FMOH has recognised the importance 
of these issues, and as a result, both podoconiosis and LF 
have now been included in the first two National Master 
Plans (2013–2015 and 2015/2016–2019/2020) for inte-
grated control of NTDs38 39 and identified as two of eight 
priority NTDs in the country, while at the same time 
aiming to move away from vertical programmes. There 
have also been calls to improve the responsiveness of the 
health system and include mental health and psychosocial 
care into the MMDP of podoconiosis and other lymphoe-
dema in Ethiopia.12 The Health Extension Programme, 
rolled out successfully in Ethiopia since 2003, now boasts 
more than 38 000 community- based health extension 
workers (HEWs), and a supervisory system to support 
them.40 Their reach has been extended through the 
women- centred Health Development Army, members of 
which link ‘model families’ with five other households to 
implement health initiatives.30 These cadres are ideally 
placed to offer simple, low- tech foot care as well as mental 
health and psychosocial support to people living with 
lymphoedema in Ethiopia,41 and to refer on people who 
need more specialised care.
To address these issues and make use of the opportuni-
ties that currently exist in Ethiopia, the FMOH requested 
implementation research to guide integration of a 
holistic care package, including physical health, mental 
health and psychosocial care interventions, for people 
with lower- limb lymphoedema into government- run 
health services. The ‘Excellence in Disability Preven-
tion Integrated across NTDs’ (EnDPoINT) research 
study (2017–2021), funded by the National Institute for 
Health Research in the UK, was set up in response to 
this and our findings are expected to inform existing 
plans for scale- up of integrated physical limb care and 
mental health and psychosocial support interventions 
across Ethiopia. The protocol for the EnDPoINT study 
is outlined below.
METHODS AND ANALYSIS
Conceptual framework for study
EnDPoINT is an implementation research study in that 
its research questions have a strong focus on implemen-
tation strategies, it includes a wide range of implemen-
tation measures, and it is being conducted in real- world 
settings and populations.42 The study takes guidance both 
from the Context and Implementation of Complex Inter-
ventions (CICI) framework, as well as from the Medical 
Research Council (MRC) framework for development 
and evaluation of complex interventions,43 44 with further 
explication and reinforcement of the different steps 
within the MRC framework through a ‘Theory of Change’ 
(ToC) approach.45
The CICI is a comprehensive framework that incorpo-
rates implementation, context and setting as dimensions, 
and interventions are seen to be operationalised within 
the macrolevel, mesolevel and microlevel. A core interest 
of EnDPoINT is to generate transferable learning as to 
the mechanisms at work during integration of targeted 
interventions into health systems within low- income and 
middle- income countries. As such, the study is a theo-
ry- led investigation, for which the CICI can provide a 
useful framework. We hope to generate rich descriptions 
of processes and mechanisms of effect, within the Ethi-
opian context, thereby enabling inference and transfer-
ability to similar settings and conditions.
The MRC framework for complex interventions 
provides a model for the practical steps involved in 
the development and evaluation of EnDPoINT’s care 
package (sitting within the broader theoretical frame-
work provided by the CICI). The MRC framework has 
been used widely and proposes four phases in the devel-
opment and evaluation of interventions: (1) develop-
ment, (2) feasibility/piloting, (3) evaluation, and (4) 
implementation; these phases are considered to be an 
iterative rather than a linear process, and can facilitate 
locally appropriate strategies to be generated. ToC is a 
structured thinking process to build a ‘causal pathway’ 
of what needs to change and why, in order to achieve 
the desired outcomes45; it enhances the MRC frame-
work for complex interventions through its emphasis on 
a theory- driven approach, which can be incorporated 
into and provide practical guidance for the different 
phases of the MRC framework.45 Figure 1 shows how 
ToC may theoretically link in and strengthen each of 
the four phases of the MRC framework on complex 
interventions. Within the EnDPoINT study, the ToC 
approach will be used within two of the four phases of 
the MRC framework: the development and feasibility/
piloting phases; for these two phases, there is good 
evidence for the practical viability and usefulness of an 
embedded ToC approach.46
Study design
EnDPoINT’s aims are to facilitate effective access to 
physical health, mental health and psychosocial care for 
people with lower limb lymphoedema caused by podo-
coniosis, LF and leprosy in selected districts in Awi zone 
in Ethiopia through integration and scale- up of a holistic 
care package into government- run health services.
The study is organised according to three phases, which 
map onto the different phases of the MRC framework for 
complex interventions.43 44 It takes an iterative approach, 
whereby the subsequent phases are dependent on find-
ings made during the previous phases. See table 1 for 
the objectives, research questions, research activities/
methods and outcome measures for each of the three 
phases.
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Phase 1 of EnDPoINT (months 1–20 of the project)—
which corresponds to phase 1 of the MRC frame-
work—entails various research activities to inform the 
development of the holistic care package. More specifi-
cally, the EnDPoINT care package builds on an MMDP 
(physical) self- care package that has previously been 
established and tested in Ethiopia for podoconiosis,47 
but with the addition of mental health and psychosocial 
components, as well as enabling provision of integrated 
care across the three diseases. The development of the 
care package within phase 1 thereby relates to: (1) the 
identification and design of these added mental health 
and psychosocial elements, while (2) integrating care 
across the three conditions, as well as (3) identifying strat-
egies for integration of the care package into the govern-
ment- run healthcare delivery system (as MMDP services 
are not yet routinely provided in Ethiopia for podoco-
niosis and LF). A bottom- up approach is used for this, 
taking into account a wide range of stakeholder views 
within multiple fora (see table 1).
Phase 2 (months 21–30)—which corresponds to phase 
2 of the MRC framework—involves a pilot study of the 
holistic care package in one subdistrict in Awi zone, which 
includes research activities to assess the care package’s 
adoption, feasibility, potential effectiveness and fidelity 
when integrated into government- run health services and 
across the three diseases, as well as the observable trends 
in the utilisation and coverage of the care package.
Phase 3 (months 31–42)—which corresponds to phases 
3 and 4 of the MRC framework—entails the scale- up of 
the holistic care package of the integrated three disease 
MMDP embedded into the primary healthcare facilities, 
and its evaluation in three selected districts in Awi zone.
Sample selection
Awi zone, in which the EnDPoINT study is being 
conducted, is 1 of 10 zones in the Amhara Region in the 
North- West of Ethiopia and is divided into 12 districts 
(or woredas). Figure 2 shows the three districts selected 
for the study: one subdistrict (a cluster that includes 
five villages) in Guagusa Shikudad district for piloting 
Figure 1 ‘Theory of Change’ (ToC) within the MRC framework for complex interventions (taken unchanged from de Silva et 
al45) (in white: taken directly from MRC framework; in blue: added elements on ToC).
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during phase 2; and three whole districts for the scale- up 
during phase 3 (Guagusa Shikudad, Ankesha Guagusa 
and Guangua). The districts were agreed between the 
EnDPoINT research team and the Ethiopian FMOH 
based on: coendemicity of podoconiosis, LF and leprosy; 
any previous or ongoing work in the districts; and acces-
sibility. The population of Awi zone is 982 942 (with each 
district/woreda having populations of between around 
8000 and 31 500), according to the latest Ethiopian 
Census in 2007.48 As for most of Ethiopia, the zone is 
largely a rural area (around 87.5% of the population48); 
Agew- Awi (59.8%) and Amhara (38.4%) are the two 
main ethnic groups, and the two most commonly spoken 
first languages are Amarigna (53.4%) and Agew- Awigna 
(45.0%). The large majority of the population (94.4%) is 
Ethiopian Orthodox Christian.48
A wide range of stakeholders are involved in EnDPoINT. 
For the qualitative research activities in all three phases of 
the study, situational analysis in phase 1, and the training 
components in phases 2 and 3, purposive sampling tech-
niques are being used to identify, approach and recruit 
key stakeholders based on their role and position. 
Members of the EnDPoINT Consortium initially contact 
key stakeholders to ask them to participate in the partic-
ular component of the study. Snowballing techniques may 
also be employed, whereby each of the key stakeholders 
identified is asked whether they are aware of any other 
key stakeholders who they think should be included.
For the qualitative work, such as the workshops, key 
informant interviews and focus groups, participants 
include members of the EnDPoINT study consortium 
who have expertise in the provision and/or receipt of 
care and the context in Ethiopia, current NTD and/
or mental health programme implementers (including 
non- governmental organisations), personnel in the NTD 
Department of the Ethiopian FMOH, policy- makers, 
health service planners, health managers and decision- 
makers, facility- based health workers (eg, primary health-
care staff, health officers, nurses), community health 
workers (CHWs), community leaders, traditional and 
religious leaders, members of service user organisations, 
as well as affected persons themselves and their families.
For the situational analysis in phase 1, key health offi-
cials and service managers are approached based on 
purposive sampling methods if necessary, though most 
of the information collected for this is being based on 
secondary data that are available in the public domain.
During the pilot study and scale- up of the care package 
in phases 2 and 3, key stakeholders are purposively 
selected to receive training to implement the various 
components (interventions) of the care package; this 
includes staff at the healthcare organisation level, zonal 
and district level health office staff, psychiatric nurses, 
senior healthcare workers, pharmacy staff, health centre 
staff (health officers and nurses), CHWs/HEWs, and 
members of the community (ie, community leads as facil-
itators of community conversations (CC)).
Affected people, that is, those with lower limb lymph-
oedema caused by podoconiosis, LF and leprosy, as well 
as their families and communities, are being included 
throughout the study; these are people identified as 
requiring care for their lymphoedema and/or comorbid 
mental ill- health. Patients are identified and recruited 
into the study based on their case identification within 
the EnDPoINT programme, that is, all adult patients (ie, 
patients over 18 years of age) within the subdistrict in 
Figure 2 Implementation districts for the Excellence in Disability Prevention Integrated across NTD (EnDPoINT) study. NTD, 
neglected tropical disease.
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phase 2 and the three districts during phase 3 who are 
identified as having either lymphoedema due to podoco-
niosis, LF or leprosy will be invited into the study (a few of 
whom will be selected as case studies). Apart from being 
beneficiaries of some interventions, affected persons will 
also potentially contribute to the delivery of some of the 
training packages and/or interventions, for example, 
by contributing to training sessions in order to provide 
a ‘lived testimony’ of living with the disease, facilitating 
self- help groups, and being actively involved in awareness- 
raising and stigma reduction activities such as CC; this is 
because of growing evidence that social contact elements 
within interventions, whereby people come into contact 
with affected persons and hear their stories, are most 
effective in reducing stigma and discrimination, and can 
contribute to increased service uptake and provision.
Only adults are being included in the study, that is, 
participants are all at least 18 years of age. All components 
of the EnDPoINT study are being conducted in either 
Amharic or English, depending on which language is 
most suitable to the particular participant group. Where 
necessary, all study instruments and materials, including 
participant information sheets and consent forms, are 
translated into Amharic, which is the official language 
of Ethiopia and can be spoken and understood by the 
majority of people in Ethiopia, including in Awi zone.
Sample size justification
For the qualitative research activities, such as key infor-
mant interviews and focus group discussions, the sample 
size is guided by the number of key stakeholders who 
are identified to take part. A data saturation approach is 
being used (ie, data collection will continue until suffi-
cient information has been obtained or where further 
data collection fails to generate new/additional themes), 
which is usual and appropriate for qualitative data collec-
tion techniques. For the workshops and training compo-
nents, the sample size will be established based on the 
number of people who are identified to be suitable and 
available. However, the sample size during any work-
shops and focus groups will not exceed 16 participants, to 
ensure that all participants have the opportunity to speak.
During phase 2, all health staff in the selected subdis-
trict are trained. During phase 3, in the three districts, 
five health workers from each health centre will be 
trained in the 13 health centres identified through the 
situational analysis in phase 1 and they will cascade the 
training to the remaining 15 staff at each health centre; 
a total of 150 HEWs in the three districts will be trained, 
which is around 10 health professionals across the three 
districts (there are 4–5 health facilities per district). 
Similarly, all adult patients who are identified within the 
single subdistrict during phase 2 and within the three 
whole districts during phase 3 as having either lymphoe-
dema caused by podoconiosis, LF or leprosy will receive 
the care interventions included in the care package (or 
will at least be offered these); we are expecting to iden-
tify around 1500–1600 people with lymphoedema due 
to podoconiosis, leprosy or LF in total across the three 
districts during phase 3 based on previous surveys that 
have been conducted (we do not have numbers available 
for LF and leprosy).
Key interventions within the care package
The EnDPoINT care package is organised according to 
three levels of the healthcare system: healthcare organ-
isation/coordination, healthcare facility and commu-
nity level. This may include the following interventions, 
though these will be finalised only after completion of 
phase 2 due to the iterative nature of the study:
 ► Healthcare organisation/coordination:
 – High- level awareness- raising and mobilisation: par-
ticipatory workshop for zonal and district health 
bureau officials, and evidence generation for best 
practice.
 – Programme management, that is, working in part-
nership with key healthcare organisation staff to 
ensure the necessary structures and budget for the 
delivery of the care package.
 – Capacity- building, that is, ‘Training of Trainers’ 
(ToT) for healthcare coordination staff about 
lymphoedema MMDP and mental health care pro-
vision, and supportive supervision, mentoring and 
coaching.
 ► Health facility:
 – Capacity building for facility- based health centre 
staff: training on lymphoedema MMDP and mental 
health care provision, and training on supply chain 
management for those staff who manage MMDP 
supplies.
 – Awareness- raising and stigma reduction: (1) partic-
ipatory workshop for facility- based staff; (2) post-
ers in health centres, including waiting rooms; (3) 
health education sessions by health facility staff for 
attendees of health facilities.
 – Case detection, assessment and treatment initia-
tion by health centre nurses and health officers, 
including training of affected persons in self- care, 
counselling and coping skills acquisition for affect-
ed persons, and mental healthcare.
 – Clinical mentoring for facility- based health workers.
 – Supportive supervision for facility- based health 
workers and CHWs.
 ► Community:
 – Capacity- building for CHWs: (1) training on 
lymphoedema MMDP and mental healthcare pro-
vision; (2) CC facilitator training.
 – Community awareness- raising and stigma reduc-
tion: (1) awareness- raising workshops for mem-
bers of the community by CHWs; (2) CC groups; 
(3) information dissemination in the community 
by CHWs (information leaflets, posters in health 
posts, mass media).
 – Active case detection and referral by CHWs.
 – Patient follow- up visits by CHWs.
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 – Community- based rehabilitation, including home 
visits, meetings, workshops, patient associations 
and self- help groups, family support groups, and 
community mobilisation.
 – Supportive supervision for CHWs.
In addition, cutting across the three levels of the health-
care system, there may also be a community advisory 
group of a wide range of stakeholders across the three 
levels. It is important to ensure high quality of the health-
care providers so that they are able to combine physical 
health, mental health and psychosocial care.
Procedures
See table 1 for an overview of the research activities/
methods conducted during each of the three phases of 
the EnDPoINT study.
Development of care package during phase 1
During phase 1, a document review of grey literature and 
a separate systematic review are conducted to inform and 
guide the development of the holistic care package and 
strategies for its integration into the routine healthcare 
delivery system in Ethiopia. To contribute further to this, 
a situational analysis/resource assessment is carried out 
to collect cross- sectional baseline data on factors relevant 
to the development and integration of the care package 
in Awi zone in Ethiopia, as well as any resources that are 
available for this, and potential risk factors. Three ToC 
workshops are conducted to map out the care package’s 
ToC in terms of defining its desired outcomes, indicators, 
interventions and measurement of the outcomes, which 
are represented graphically on a ToC map along with an 
accompanying narrative describing the key pathways and 
assumptions, as well as to encourage stakeholder buy- in 
to the study.45 Key informant interviews and focus groups 
are then conducted, to test the feasibility, acceptability 
and appropriateness of the draft care package, as well 
as to assess key aspects of the ToC, for example, some of 
the key assumptions identified during the workshops.45 
Participants of this qualitative work and the ToC work-
shops include affected persons, caregivers and various 
health providers. The care package and its associated 
training materials are discussed and finalised following a 
workshop with members of the EnDPoINT research team 
and FMOH in Ethiopia. A separate manuscript will be 
prepared detailing the phase 1 activities further.
A large focus of the research content during all of the 
phase 1 research activities outlined above is the mental 
health and psychosocial components of the care package, 
including the stigma reduction elements, as well as how 
to integrate care across the three diseases and into the 
routine healthcare system, as this is where there are gaps 
in knowledge within the Ethiopian context. In line with 
this, based on the research activities during phase 1, 
already- existing MMDP guidelines for podoconiosis and 
LF are adapted as part of the project to include leprosy 
and mental health components, to inform the training 
materials.
Piloting of care package during phase 2
During the pilot study in one subdistrict in Awi zone, the 
main training elements and interventions of the care 
package are tested through a mixed- methods design, to 
establish their adoption, feasibility, acceptability, fidelity, 
potential effectiveness, their readiness for scale up, costs 
of the interventions, and the suitability of the training 
and training materials. This involves implementing the 
interventions, including their training components, as 
outlined in the section on the draft care package above, 
and evaluating them. During the pilot study, the inter-
ventions covered by the training are implemented for 
3 months.
Quantitative evaluations of the interventions and asso-
ciated trainings are conducted at baseline and 3- month 
follow- up through surveys with those affected people 
who are receiving the treatment interventions within the 
care package, to measure changes in patient outcomes 
in relation to physical health, mental health/well- being, 
quality of life, stigma and discrimination (including social 
support), disability and healthcare use and costs; surveys 
with members of the community within which the affected 
persons live, to assess changes in stigma and ‘change of 
knowledge, attitudes and practice’ (KAP); as well as an 
evaluation of the training through assessment of KAP of 
health workers receiving the training and their satisfac-
tion with the training. In addition, qualitative assessments 
are carried out through observation of the interventions 
being implemented; and key informant interviews and 
focus group discussions with those stakeholders who 
received the training and delivered the interventions, 
as well as the recipients of the interventions (ie, people 
affected by podoconiosis, LF and leprosy). Table 2 shows 
the outcomes that are assessed in phase 2 together with 
how these are measured; see also right- hand column in 
table 1 for the outcome measurements used. All measure-
ment tools are administered by data collectors rather than 
being completed by participants themselves, meaning 
that illiterate participants are not disadvantaged.
The care package, as well as the training materials, 
may be revised further based on the results of the pilot 
study (success criteria will be established a priori), and 
there may be further pilot testing if major challenges 
are encountered that will need to be addressed further, 
before being scaled up in three whole districts.
Scale-up of care package during phase 3
The scale- up and evaluation of the care package during 
phase 3 of the EnDPoINT study will involve implemen-
tation of all interventions at all three levels of the health 
system (healthcare organisation/coordination, health 
facility and community level) in three districts in Awi 
zone. While the exact interventions that will be included 
in the care package for scale- up will depend on the find-
ings of phases 1 and 2, the general potential structure of 
the training for the various interventions included in the 
care package is depicted in figure 3.
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The scale- up of the care package interventions during 
phase 3 will be implemented, followed up and evaluated 
over a period of 1 year. Affected persons will be followed 
up every month for the first 3 months and then at 12 
months. A mixed- method approach will be used for the 
evaluation of the care package. A pre–post design will be 
employed for quantitative evaluation of the care package, 
with data collected at baseline (ie, before training or 
any of the intervention components commence), and at 
3- month and 12- month follow- up; data will be collected 
Table 2 Outcomes and their measures during phases 2 and 3 of the Excellence in Disability Prevention Integrated across 
NTDs (EnDPoINT) study
Type of outcomes Specific outcome Outcome measures
Implementation 
outcomes
Adoption Qualitatively (KIIs/FGDs, observation)
Feasibility Qualitatively (KIIs/FGDs, observation); cost of training/
interventions; number of cases identified, assessed and 
treated
Acceptability (by providers and affected persons) Qualitatively (KIIs/FGDs, observation)
Appropriateness Qualitatively (KIIs/FGDs, observation)
Fidelity Qualitatively (KIIs/FGDs, observation)
Readiness for scale- up Qualitatively (KIIs/FGDs, observation)
Economic characteristics of study participants Purposely designed questionnaire
Resource use associated with delivering the care 
package
Project financial records and interviews with project 
manager(s)
Effectiveness (patient 
level)
MMDP assessment Swelling circumference (physical measurements); 
frequency of acute attacks (patient self- report); stage/
grade of affected limb (physical assessment); signs 
of infection (physical assessment); wounds (physical 
assessment); nodules (physical assessment)
Depression Patient Health Questionnaire 9
Suicidal ideation and action CIDI questions
Alcohol use Fast Alcohol Screening Test
Quality of life Dermatology Life Quality Index
Disability WHO Disability Assessment Schedule 2.0
Internalised stigma Internalised stigma related to lymphoedema
Discrimination Discrimination and Stigma Scale 12
Social support Social Support Scale (OSLO-3)
Happiness Happiness index
Use of primary care/cost Purposely designed questionnaire
Use of hospital care/cost Purposely designed questionnaire
Use of medication/cost Purposely designed questionnaire
Personal expenses Purposely designed questionnaire
Days off work due to illness/cost Purposely designed questionnaire
Effectiveness 
(community level)
Coverage Number of cases identified, assessed and treated; 
proportion of cases detected who are then treated; 
number of affected persons reached with MMDP supplies; 
number of affected persons who have received mental 
healthcare; contact coverage
KAP lymphoedema Purposely designed questionnaire
Social distance Social Distance Scale (SDS)
Effectiveness (facility 
level)
KAP lymphoedema Purposely designed questionnaire
KAP mental health Purposely designed questionnaire
Other outcomes Suitability of training and training materials Qualitatively (KIIs/FGDs, observation)
Satisfaction with training Purposely designed questionnaire; qualitatively (KIIs/
FGDs, observation)
FGDs, focus group discussions; KAP, knowledge, attitudes and practice; KIIs, key informant interviews; MMDP, morbidity management 
and disability prevention.
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on coverage, as well as implementation, clinical (phys-
ical health, mental health and psychosocial), economic 
(including total costs of the care package) and social 
outcomes (see table 1). The questionnaires for evalua-
tion are the same ones used during the phase 2 piloting, 
though these may be refined and improved based on the 
piloting. A detailed monitoring and evaluation plan for 
phase 3 will be developed based on the results in phase 2.
For the qualitative evaluation of the care package 
during phase 3, key informant interviews and focus group 
discussions will be carried out with a wide range of stake-
holders who have been involved in the implementation of 
the care package (eg, affected persons and their families, 
health facility staff, community health workers, health 
facility management staff, district- level health staff, etc); 
these will be carried out at two time points, once towards 
the beginning of the scale- up period and then again 
towards the end of the scale- up period. The topic guides 
and interview questions for the key informant interviews 
and focus group discussions will be developed once phase 
2 has been completed.
Outcomes to be measured
Tables 1 and 2 detail the outcomes measured during 
EnDPoINT, as well as the time points and methods that 
will be used to measure these.
Data analysis plan
Qualitative data (such as from the key informant inter-
views and focus group discussions) will be analysed using 
thematic analysis with the assistance of a qualitative soft-
ware package (NVivo). Validity (dependability) of data 
will be assessed through the identification of the initial 
codes by an experienced qualitative researcher and 
agreeing on the framework in which the data will be 
presented, presentation of initial findings to experienced 
academics to assess the plausibility, and including single 
counting of identified events/phenomena. Validity assur-
ance will also involve checking of alignment of research 
questions, interview guides, sampling procedures and 
so on. For quantitative data collected during phases 2 
and 3, descriptive analyses (such as simple counts and 
frequencies or means and SD) will be used, as well as the 
% change before and after the implementation of the 
interventions, together with 95% CIs). A detailed data 
analysis plan will be produced for the evaluation of the 
care package during phases 2 and 3. The results from 
the various research activities throughout the study will 
be triangulated to develop and finalise the holistic care 
package and strategies for its integration into the routine 
healthcare delivery system in Awi zone in Ethiopia.
Patient and public involvement
Affected persons and their communities are being fully 
engaged in the research process throughout the entire 
EnDPoINT project. EnDPoINT is being supported by 
a consortium, which includes patient representatives 
alongside researchers, health professionals, FMOH 
staff and other stakeholders, whose remit is to provide 
input, guidance and advice throughout the programme 
of research. Affected persons and community members 
are partnering with the EnDPoINT study team for the 
design of the study and care package. This includes the 
development and implementation of the interventions; 
the development of materials, such as training mate-
rials; the sharing and identification of findings; and the 
identification of appropriate channels and venues for 
the dissemination of results. Affected people and their 
families and communities are included within the work-
shops and qualitative aspects of the work, such as the key 
informant interviews and focus group discussions. The 
situational analysis ensures that the interventions fit in 
with the local context and build on the strengths and 
assets of the community. Where possible, members of the 
local community are being employed to collect data, to 
facilitate capacity building of community members. The 
EnDPoINT Consortium will contribute to various outputs 
for dissemination. Affected persons and community 
members are therefore being involved in the entire study 
process, both as coresearchers and as participants of the 
study.
Economic analysis
We aim to cost the holistic package of physical health, 
mental health and psychosocial care interventions for 
people with lower limb lymphoedema caused by podoco-
niosis, LF or leprosy, and the integration of this package 
into the routine healthcare delivery system (phases 2 and 
3), thereby ensuring that the care package represents 
value for money. Intervention activities will be costed at 
three levels:
Figure 3 Potential training structure within the Excellence 
in Disability Prevention Integrated across NTD (EnDPoINT) 
study. MMDP, morbidity management and disability 
prevention.
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1. Healthcare organisation/coordination level: 
awareness- raising activities, programme management 
and training healthcare organisation staff.
2. Healthcare facility level: awareness- raising activities, 
case detection, treatment, staff training in health ed-
ucation for patient physical health self- care, mental 
health and psychosocial support.
3. Community level: awareness- raising activities, train-
ing and supervision of CHWs, active case detection by 
CHWs, providing community- based healthcare and 
rehabilitation.
The main cost components will be identified in the 
pilot study (phase 2); cost data will be collected during 
the scale- up of the care package intervention (phase 3). A 
microcosting approach will include a bottom- up construc-
tion of costs associated with setting up and delivering the 
package. The costs of training healthcare professionals 
will include: time spent in preparing and attending the 
training sessions, room rental, training materials, travel 
expenses and administration costs. The costs of delivering 
the healthcare package will include: costs of lymphoe-
dema treatment supplies (eg, soap, ointment, bandages, 
gloves, antiseptics), infrastructure costs and additional 
staff salaries/time. Costs will be collected from financial 
records and interviews with programme managers. We 
will also collect data on the socioeconomic characteristics 
of study participants, housing, economic activities, use of 
healthcare services and out- of- pocket expenses related 
to the lower limb lymphoedema. Direct costs will cover 
contacts with healthcare professionals, pharmacists and 
traditional healers, medication and hospitalisations with 
respect to the conditions. Indirect costs will include addi-
tional costs to the individuals and their families (eg, travel 
to hospital, accommodation, food and borrowing money 
from family/relatives/community). Economic data will 
be collected using a purpose- designed questionnaire.
ETHICS AND DISSEMINATION
Ethics
Ethical approval has already been obtained from the 
Brighton and Sussex Medical School Research Gover-
nance and Ethics Committee in the UK, as well as the 
Institutional Review Board of the College of Health 
Sciences at Addis Ababa University in Ethiopia.
All people who are participating in the research (all 
over 18 years old) are given a participant information 
sheet (outlining the study’s research aims, procedures, 
and potential risks and benefits) and are required to give 
their written consent to take part (or verbal consent with 
a witness declaration by the interviewer where a person 
is illiterate); if a person does not consent to take part, 
that person is excluded. However, those people who 
are involved purely in the implementation of the care 
package, for example, those who are receiving training 
on self- care for lymphoedema or who are taking part 
in a stakeholder meeting, are not required to give their 
informed consent, though they are not obliged to be 
involved. All participants are able to withdraw from the 
study at any time without having to give a reason or any 
detrimental consequences, for instance in regard to their 
care, treatment or employment, until data have been 
aggregated.
Confidentiality and anonymity of data are ensured 
throughout the study process, from data collection to 
data storage, analysis and publication. Structured, multi-
level precautions are taken to safeguard the confidential 
nature of the information gathered, and to ensure the 
anonymity of participants, for example, by using personal 
identifiers instead of names, with identifying data kept 
separately from the identifying codes used on the data 
collection sheets and databases. Only anonymised data 
will be used for data analyses. All data are being stored 
in a secure OneDrive folder, which can only be accessed 
by members of the team for whom access to the data are 
essential.
Dissemination
An EnDPoINT publication plan has already been devel-
oped, which includes several planned articles for publica-
tion in scientific journals. It is likely that the results of the 
study will also be shared through various other forums, 
including to the larger scientific community through 
conferences, but also to policy- makers and healthcare 
staff, and other participants of the study. This will likely 
be in the form of a workshop at the end of the study and/
or through the distribution of a summary document and/
or policy brief(s) with an overview of the main results of 
the study.
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